Annals of surgical oncology · 2025
Staging Laparoscopy in Gastric Cancer Patients Treated with Curative Intent: A European GASTRODATA Cohort Study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sędłak Katarzyna, Kobiałka Sebastian, Pelc Zuzanna, Endo Yutaka, Gockel Ines, van Sandick Johanna, Baiocchi Gian Luca, Wijnhoven Bas, Gisbertz Suzanne, Pera Manuel, Morgagni Paolo, Framarini Massimo, Hoelscher Arnulf, Moenig Stefan, Kołodziejczyk Piotr, Piessen Guillaume, Eveno Clarisse, da Costa Paulo Matos, Davies Andrew, Allum William, Romario Uberto Fumagalli, Rosati Ricardo, Reim Daniel, Santos Lucio Lara, D'ugo Domenico, De Manzoni Giovanni, Kielan Wojciech, Schneider Paul M, Pawlik Timothy M, Polkowski Wojciech, Rawicz-Pruszyński Karol
Аннотация
BACKGROUND: In current guidelines, staging laparoscopy (SL) is recommended in patients with locally advanced gastric cancer (GC). This study aimed to assess the clinical practice of SL and its association with administration of systemic treatment in a European cohort of GC patients (GASTRODATA).
METHODS: In this retrospective cohort study, patients with locally advanced GC who underwent multimodal treatment in 24 European centers were analyzed. Patients with early (cT1) or metastatic GC at diagnosis and those with missing data on chemotherapy administration were excluded.
RESULTS: Of 2558 patients, 1726 were selected, with 562 (32.6%) undergoing SL. Patients who did not undergo SL were older (72 vs. 65 years; p < 0.001) and had higher Charlson Comorbidity Index scores (≥ 2: 33.8% vs. 20.5%; p < 0.001). These patients had more complications (30.9% vs. 24.4%; p = 0.005), higher 90-day mortality (4.7% vs. 2.3%; p = 0.017), and were less likely to receive neoadjuvant (35% vs. 78.6%; p < 0.001) or adjuvant (27.1% vs. 33.8%; p = 0.005) chemotherapy. Non-SL patients had higher rates of serosal invasion (pT4: 38.0% vs. 26.0%; p < 0.001) and lymph node metastasis (63.5% vs. 60.4%; p = 0.004).
CONCLUSIONS: SL was performed in one-third of individuals with locally advanced GC. Absence of SL was associated with higher T-stage discrepancy and decreased utilization of multimodal treatment.
METHODS: In this retrospective cohort study, patients with locally advanced GC who underwent multimodal treatment in 24 European centers were analyzed. Patients with early (cT1) or metastatic GC at diagnosis and those with missing data on chemotherapy administration were excluded.
RESULTS: Of 2558 patients, 1726 were selected, with 562 (32.6%) undergoing SL. Patients who did not undergo SL were older (72 vs. 65 years; p < 0.001) and had higher Charlson Comorbidity Index scores (≥ 2: 33.8% vs. 20.5%; p < 0.001). These patients had more complications (30.9% vs. 24.4%; p = 0.005), higher 90-day mortality (4.7% vs. 2.3%; p = 0.017), and were less likely to receive neoadjuvant (35% vs. 78.6%; p < 0.001) or adjuvant (27.1% vs. 33.8%; p = 0.005) chemotherapy. Non-SL patients had higher rates of serosal invasion (pT4: 38.0% vs. 26.0%; p < 0.001) and lymph node metastasis (63.5% vs. 60.4%; p = 0.004).
CONCLUSIONS: SL was performed in one-third of individuals with locally advanced GC. Absence of SL was associated with higher T-stage discrepancy and decreased utilization of multimodal treatment.